A local TV segment looks at why Lilly's experimental retatrutide is getting so much coverage next to Ozempic.
Recap by typeshit. Full story at WFTV Channel 9.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
Gen Z use beats every other generation, and appearance was its top reason. Korean regulators are also weighing tighter controls on Wegovy and Mounjaro.
Only 503A pharmacies are covered, and one Florida compounder says the whole sector couldn't meet demand. Public Citizen says Kennedy undermined the FDA.
Loading…